|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions affects response to substance increases export affects transport decreases expression increases transport increases import decreases uptake increases response to substance |
ISO EXP |
5,7-dimethoxyflavone inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; 5-hydroxyflavone inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; 5-methoxyflavone inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; [5-Methoxypsoralen results in decreased activity of ABCB1 protein] which results in decreased export of and results in increased abundance of Daunorubicin; [Carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]] which results in decreased susceptibility to Daunorubicin; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of ABCB1 mRNA; [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of ABCB1 mRNA; [Methoxsalen results in decreased activity of ABCB1 protein] which results in decreased export of and results in increased abundance of Daunorubicin; [Sodium Azide co-treated with Iodoacetates] inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin]; ABCB1 mutant form promotes the reaction [Daunorubicin results in decreased expression of ABCB1 mRNA]; ABCB1 mutant form promotes the reaction [Daunorubicin results in decreased expression of ABCB1 protein]; ABCB1 mutant form promotes the reaction [Magnetite Nanoparticles results in increased susceptibility to Daunorubicin]; Amiodarone inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; aurapten promotes the reaction [ABCB1 protein results in increased import of Daunorubicin]; azelastine inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; baicalein inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; baicalein inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; biochanin A inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; biochanin A promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; Carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; Cyclosporine inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin]; Cyclosporine inhibits the reaction [ABCB1A protein results in increased export of Daunorubicin]; Daunorubicin promotes the reaction [ABCB1 mutant form results in decreased expression of ABCB1 protein]; Daunorubicin promotes the reaction [Magnetite Nanoparticles results in decreased expression of ABCB1 protein]; desethylamiodarone inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; desmethylazelastine inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; dihydromyricetin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; flavone inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; flavone promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; galangin inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; glycitein inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; glycitein promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; isovitexin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; kaempferide inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; kaempferide inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; kaempferol inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; Luteolin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; Magnetite Nanoparticles promotes the reaction [ABCB1 mutant form promotes the reaction [Daunorubicin results in decreased expression of ABCB1 mRNA]]; Magnetite Nanoparticles promotes the reaction [ABCB1 mutant form promotes the reaction [Daunorubicin results in decreased expression of ABCB1 protein]]; Magnetite Nanoparticles promotes the reaction [ABCB1 mutant form results in increased susceptibility to Daunorubicin]; Magnetite Nanoparticles promotes the reaction [Daunorubicin promotes the reaction [ABCB1 mutant form results in decreased expression of ABCB1 protein]]; Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of ABCB1 mRNA]; Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of ABCB1 protein]; Mitotane inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin]; naringenin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; naringenin inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; nobiletin promotes the reaction [ABCB1 protein results in increased import of Daunorubicin]; puerarin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; Quercetin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; schaftoside inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; Sesquiterpenes analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Daunorubicin]; Silybin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; Silybin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; tangeretin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; valspodar inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin]; Verapamil inhibits the reaction [[5-Methoxypsoralen results in decreased activity of ABCB1 protein] which results in decreased export of and results in increased abundance of Daunorubicin]; Verapamil inhibits the reaction [[Methoxsalen results in decreased activity of ABCB1 protein] which results in decreased export of and results in increased abundance of Daunorubicin]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin] ABCB1A affects the susceptibility to Daunorubicin Daunorubicin inhibits the reaction [ABCB1 results in increased transport of estradiol-17 beta-glucuronide] ABCB1 protein results in increased export of Daunorubicin; ABCB1A protein results in increased export of Daunorubicin ABCB1 protein affects the transport of Daunorubicin Daunorubicin results in decreased expression of ABCB1 mRNA; Daunorubicin results in decreased expression of ABCB1 protein ABCB1 affects the susceptibility to Daunorubicin; ABCB1 protein affects the susceptibility to Daunorubicin |
CTD |
PMID:9794924 PMID:9815696 PMID:10617675 PMID:11231118 PMID:12107549 PMID:12174371 PMID:12526924 PMID:12642476 PMID:12708479 PMID:15466210 PMID:16636798 PMID:18955043 PMID:20957165 PMID:22114476 PMID:24954033 PMID:29079042 PMID:34217736 More...
|
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb8 |
ATP binding cassette subfamily B member 8 |
decreases expression |
EXP |
Daunorubicin results in decreased expression of ABCB8 mRNA |
CTD |
PMID:27090888 |
|
NCBI chr 4:10,766,206...10,783,598
Ensembl chr 4:10,768,281...10,783,589
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
affects export decreases response to substance increases secretion affects response to substance multiple interactions decreases uptake |
ISO |
ABCC1 protein affects the export of Daunorubicin ABCC1 results in decreased susceptibility to Daunorubicin ABCC1 protein results in increased secretion of Daunorubicin ABCC1 affects the susceptibility to Daunorubicin; ABCC1 protein affects the susceptibility to Daunorubicin Benzbromarone inhibits the reaction [ABCC1 protein results in increased secretion of Daunorubicin]; Camptothecin inhibits the reaction [ABCC1 results in decreased susceptibility to Daunorubicin]; Folic Acid deficiency inhibits the reaction [ABCC1 protein results in increased secretion of Daunorubicin]; homocamptothecin inhibits the reaction [ABCC1 protein results in increased secretion of Daunorubicin]; PAK 104P inhibits the reaction [ABCC1 protein affects the export of Daunorubicin]; Verapamil inhibits the reaction [ABCC1 protein affects the export of Daunorubicin] ABCC1 protein results in decreased susceptibility to Daunorubicin; ABCC1 results in decreased susceptibility to Daunorubicin Daunorubicin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Glucose inhibits the reaction [Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Daunorubicin]]; Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Daunorubicin]; Verapamil inhibits the reaction [ABCC1 protein results in decreased uptake of Daunorubicin] |
CTD |
PMID:7954421 PMID:8968083 PMID:9096673 PMID:9334814 PMID:10856430 PMID:12088114 PMID:12115804 PMID:12174371 PMID:12657726 PMID:15041471 PMID:15498506 PMID:18451141 More...
|
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects response to substance multiple interactions |
ISO |
ABCC2 affects the susceptibility to Daunorubicin [5-methoxypsoralen results in decreased activity of ABCC2 protein] which results in decreased export of and results in increased abundance of Daunorubicin; [Methoxsalen results in decreased activity of ABCC2 protein] which results in decreased export of and results in increased abundance of Daunorubicin; Indomethacin inhibits the reaction [[5-methoxypsoralen results in decreased activity of ABCC2 protein] which results in decreased export of and results in increased abundance of Daunorubicin]; Indomethacin inhibits the reaction [[Methoxsalen results in decreased activity of ABCC2 protein] which results in decreased export of and results in increased abundance of Daunorubicin] |
CTD |
PMID:18451141 PMID:29079042 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions increases expression |
ISO |
Dactinomycin inhibits the reaction [Daunorubicin results in increased expression of ABCG2 mRNA] |
CTD |
PMID:20019844 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
decreases response to substance |
ISO |
ABL1 results in decreased susceptibility to Daunorubicin |
CTD |
PMID:12410571 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
decreases expression |
ISO |
Daunorubicin results in decreased expression of ACTA1 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr19:51,883,713...51,886,725
Ensembl chr19:51,883,715...51,886,742
|
|
G |
Agrn |
agrin |
increases expression |
ISO |
Daunorubicin results in increased expression of AGRN mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 5:166,749,306...166,782,212
Ensembl chr 5:166,749,310...166,786,003
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions increases expression |
EXP |
telmisartan inhibits the reaction [Daunorubicin results in increased expression of AGTR1A protein] |
CTD |
PMID:20888384 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
increases reduction affects metabolic processing multiple interactions increases metabolic processing |
ISO |
AKR1A1 protein results in increased reduction of Daunorubicin AKR1A1 SNP affects the metabolism of Daunorubicin [AKR1A1 results in increased metabolism of Daunorubicin] which results in increased chemical synthesis of daunorubicinol |
CTD |
PMID:18276838 PMID:18322072 |
|
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
increases reduction |
ISO |
AKR1B1 protein results in increased reduction of Daunorubicin |
CTD |
PMID:10510318 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
decreases response to substance increases reduction multiple interactions |
ISO |
AKR1B10 protein results in decreased susceptibility to Daunorubicin AKR1B10 protein results in increased reduction of Daunorubicin [AKR1B10 protein results in increased reduction of Daunorubicin] which results in increased chemical synthesis of daunorubicinol; ciprofibrate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; Fenofibrate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; fenofibric acid inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; pirinixic acid inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; sorbinil inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; zopolrestat inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin] |
CTD |
PMID:19028477 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
increases metabolic processing increases reduction decreases response to substance multiple interactions |
ISO |
AKR1C3 protein results in increased metabolism of Daunorubicin; AKR1C3 results in increased metabolism of Daunorubicin AKR1C3 protein results in increased reduction of Daunorubicin AKR1C3 protein results in decreased susceptibility to Daunorubicin [AKR1C3 protein results in increased metabolism of Daunorubicin] which results in increased abundance of daunorubicinol; [AKR1C3 protein results in increased reduction of Daunorubicin] which results in increased abundance of daunorubicinol; [Tretinoin results in decreased activity of AKR1C3 protein] which results in increased susceptibility to Daunorubicin; dinaciclib inhibits the reaction [AKR1C3 protein results in decreased susceptibility to Daunorubicin]; midostaurin inhibits the reaction [AKR1C3 protein results in decreased susceptibility to Daunorubicin]; midostaurin inhibits the reaction [AKR1C3 protein results in increased metabolism of Daunorubicin]; NVP-BKM120 inhibits the reaction [AKR1C3 protein results in increased reduction of and results in decreased susceptibility to Daunorubicin]; Tretinoin inhibits the reaction [[AKR1C3 protein results in increased metabolism of Daunorubicin] which results in increased abundance of daunorubicinol]; Tretinoin inhibits the reaction [AKR1C3 protein results in increased metabolism of Daunorubicin] |
CTD |
PMID:20837989 PMID:29992508 PMID:30703376 PMID:32588086 PMID:33025066 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases response to substance |
ISO |
AKT1 protein results in decreased susceptibility to Daunorubicin |
CTD |
PMID:22252735 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Angpt1 |
angiopoietin 1 |
decreases expression |
EXP |
Daunorubicin results in decreased expression of ANGPT1 mRNA; Daunorubicin results in decreased expression of ANGPT1 protein |
CTD |
PMID:16626513 |
|
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Angpt2 |
angiopoietin 2 |
increases expression |
EXP |
Daunorubicin results in increased expression of ANGPT2 mRNA; Daunorubicin results in increased expression of ANGPT2 protein |
CTD |
PMID:16626513 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Ank2 |
ankyrin 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of ANK2 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 2:215,378,028...215,954,015
Ensembl chr 2:215,379,680...215,862,923
|
|
G |
Ankrd1 |
ankyrin repeat domain 1 |
decreases expression |
EXP |
Daunorubicin results in decreased expression of ANKRD1 mRNA |
CTD |
PMID:9278441 |
|
NCBI chr 1:233,815,851...233,834,891
Ensembl chr 1:233,815,851...233,834,919
|
|
G |
Ano3 |
anoctamin 3 |
affects response to substance |
ISO |
ANO3 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 3:97,235,671...97,550,090
Ensembl chr 3:97,238,354...97,550,154
|
|
G |
Anxa2 |
annexin A2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of ANXA2 mRNA; Daunorubicin results in decreased expression of ANXA2 protein |
CTD |
PMID:21223737 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Anxa4 |
annexin A4 |
increases expression |
ISO |
Daunorubicin results in increased expression of ANXA4 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
multiple interactions |
ISO |
APEX1 protein results in increased reduction of and results in increased susceptibility to Daunorubicin |
CTD |
PMID:10190555 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Apob |
apolipoprotein B |
increases expression |
EXP |
Daunorubicin results in increased expression of APOB protein |
CTD |
PMID:7637207 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoc3 |
apolipoprotein C3 |
increases expression |
EXP |
Daunorubicin results in increased expression of APOC3 protein |
CTD |
PMID:7637207 |
|
NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583
|
|
G |
Ar |
androgen receptor |
increases activity decreases activity |
ISO |
Daunorubicin results in increased activity of AR protein Daunorubicin results in decreased activity of AR protein |
CTD |
PMID:25257666 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Atm |
ATM serine/threonine kinase |
increases expression |
ISO |
Daunorubicin results in increased expression of ATM mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp1a2 |
ATPase Na+/K+ transporting subunit alpha 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of ATP1A2 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr13:84,729,597...84,754,544
Ensembl chr13:84,729,601...84,754,544
|
|
G |
Atxn1 |
ataxin 1 |
decreases expression |
EXP |
Daunorubicin results in decreased expression of ATXN1 mRNA |
CTD |
PMID:27090888 |
|
NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360
|
|
G |
Aurka |
aurora kinase A |
decreases expression |
ISO |
Daunorubicin results in decreased expression of AURKA protein |
CTD |
PMID:23872705 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Bard1 |
BRCA1 associated RING domain 1 |
affects expression |
ISO |
Daunorubicin affects the expression of BARD1 mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
[bromotetrandrine co-treated with Daunorubicin] results in increased expression of BAX mRNA; [bromotetrandrine co-treated with Daunorubicin] results in increased expression of BAX protein; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in increased expression of BAX mRNA; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in increased expression of BAX protein; [Daunorubicin co-treated with bromotetrandrine] results in increased expression of BAX mRNA; [Daunorubicin co-treated with bromotetrandrine] results in increased expression of BAX protein; [Daunorubicin co-treated with Magnetite Nanoparticles] results in increased expression of BAX mRNA; [Magnetite Nanoparticles co-treated with Daunorubicin] promotes the reaction [bromotetrandrine results in increased expression of BAX protein]; [Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of BAX mRNA; [Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of BAX protein; bromotetrandrine promotes the reaction [[ferric oxide co-treated with ferrous oxide co-treated with Daunorubicin] results in increased expression of BAX protein]; bromotetrandrine promotes the reaction [[Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of BAX mRNA]; Magnetite Nanoparticles promotes the reaction [[bromotetrandrine co-treated with Daunorubicin] results in increased expression of BAX mRNA] Daunorubicin results in increased expression of BAX mRNA |
CTD |
PMID:19421372 PMID:19918366 PMID:21720514 PMID:26537877 PMID:28940058 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions affects expression decreases expression decreases response to substance |
ISO |
[Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [bromotetrandrine co-treated with Daunorubicin] results in decreased expression of BCL2 protein; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2 mRNA; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2 protein; [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BCL2 mRNA; [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BCL2 protein; [Daunorubicin co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2 mRNA; [Magnetite Nanoparticles co-treated with Daunorubicin] promotes the reaction [bromotetrandrine results in decreased expression of BCL2 protein]; [Magnetite Nanoparticles co-treated with Daunorubicin] results in decreased expression of BCL2 protein; bromotetrandrine promotes the reaction [[Magnetite Nanoparticles co-treated with Daunorubicin] results in decreased expression of BCL2 protein]; bromotetrandrine promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA]; bromotetrandrine promotes the reaction [Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA]]; Magnetite Nanoparticles promotes the reaction [bromotetrandrine promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA]]; Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA] Daunorubicin affects the expression of BCL2 mRNA BCL2 results in decreased susceptibility to Daunorubicin |
CTD |
PMID:19421372 PMID:19918366 PMID:21302442 PMID:21595920 PMID:21720514 PMID:27780733 More...
|
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[Daunorubicin co-treated with TNFSF10 protein] results in increased expression of BID protein |
CTD |
PMID:12780785 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions increases expression affects expression |
ISO |
[bromotetrandrine co-treated with Daunorubicin] results in decreased expression of BIRC5 mRNA; [bromotetrandrine co-treated with Daunorubicin] results in decreased expression of BIRC5 protein; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BIRC5 mRNA; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BIRC5 protein; [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BIRC5 mRNA; [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BIRC5 protein Daunorubicin results in increased expression of BIRC5 mRNA; Daunorubicin results in increased expression of BIRC5 protein Daunorubicin affects the expression of BIRC5 mRNA |
CTD |
PMID:16638212 PMID:21362215 PMID:21720514 PMID:27780733 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Cab39 |
calcium binding protein 39 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CAB39 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:86,463,008...86,524,545
Ensembl chr 9:86,463,095...86,524,544
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CACNA1G mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752
|
|
G |
Cacna1s |
calcium voltage-gated channel subunit alpha1 S |
affects response to substance |
ISO |
CACNA1S affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr13:47,493,949...47,564,194
Ensembl chr13:47,493,949...47,564,318
|
|
G |
Cacna2d2 |
calcium voltage-gated channel auxiliary subunit alpha2delta 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CACNA2D2 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 8:108,072,208...108,203,516
Ensembl chr 8:108,072,454...108,203,173
|
|
G |
Casp3 |
caspase 3 |
multiple interactions affects expression increases activity |
ISO |
[bromotetrandrine co-treated with Daunorubicin] results in increased expression of CASP3 mRNA; [bromotetrandrine co-treated with Daunorubicin] results in increased expression of CASP3 protein; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in increased expression of CASP3 mRNA; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in increased expression of CASP3 protein; [Daunorubicin co-treated with bromotetrandrine] results in increased expression of CASP3 mRNA; [Daunorubicin co-treated with bromotetrandrine] results in increased expression of CASP3 protein; [Daunorubicin co-treated with Magnetite Nanoparticles] results in increased expression of CASP3 mRNA; [Daunorubicin co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; [Magnetite Nanoparticles co-treated with Daunorubicin] promotes the reaction [bromotetrandrine results in increased expression of CASP3 protein]; [Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of CASP3 mRNA; [Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of CASP3 protein; bromotetrandrine promotes the reaction [[ferric oxide co-treated with ferrous oxide co-treated with Daunorubicin] results in increased expression of CASP3 protein]; bromotetrandrine promotes the reaction [[Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of CASP3 mRNA]; Magnetite Nanoparticles promotes the reaction [[bromotetrandrine co-treated with Daunorubicin] results in increased expression of CASP3 mRNA] Daunorubicin affects the expression of CASP3 mRNA Daunorubicin results in increased activity of CASP3 protein |
CTD |
PMID:10766178 PMID:12780785 PMID:17699722 PMID:17965967 PMID:19421372 PMID:19698806 PMID:19918366 PMID:21720514 PMID:25003661 PMID:27780733 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[Daunorubicin co-treated with TNFSF10 protein] results in increased activity of CASP8 protein |
CTD |
PMID:12780785 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
affects expression |
ISO |
Daunorubicin affects the expression of CASP9 mRNA |
CTD |
PMID:27780733 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
affects response to substance |
ISO |
CAT protein affects the susceptibility to Daunorubicin |
CTD |
PMID:11178967 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cavin4 |
caveolae associated protein 4 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CAVIN4 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 5:62,996,975...63,004,819
Ensembl chr 5:62,996,865...63,007,678
|
|
G |
Cbr3 |
carbonyl reductase 3 |
affects response to substance affects metabolic processing |
ISO |
CBR3 gene SNP affects the susceptibility to Daunorubicin CBR3 protein affects the metabolism of Daunorubicin; CBR3 protein alternative form affects the metabolism of Daunorubicin |
CTD |
PMID:20007405 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CCL4 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,466,469...68,467,941
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccnd3 |
cyclin D3 |
increases expression |
ISO |
Daunorubicin results in increased expression of CCND3 mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
affects expression |
ISO |
Daunorubicin affects the expression of CCNE1 mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccng2 |
cyclin G2 |
increases expression |
ISO |
Daunorubicin results in increased expression of CCNG2 mRNA |
CTD |
PMID:18754885 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Cd34 |
CD34 molecule |
decreases expression |
EXP |
Daunorubicin results in decreased expression of CD34 mRNA |
CTD |
PMID:27090888 |
|
NCBI chr13:106,480,074...106,499,462
Ensembl chr13:106,480,043...106,499,832
|
|
G |
Cdc25a |
cell division cycle 25A |
increases expression |
ISO |
Daunorubicin results in increased expression of CDC25A mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701
|
|
G |
Cdh13 |
cadherin 13 |
affects response to substance |
ISO |
CDH13 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Daunorubicin results in increased expression of CDKN1A; Daunorubicin results in increased expression of CDKN1A mRNA; Daunorubicin results in increased expression of CDKN1A protein |
CTD |
PMID:12112851 PMID:12656675 PMID:23872705 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions affects expression |
EXP |
fasudil affects the reaction [Daunorubicin affects the expression of CDKN1B mRNA] |
CTD |
PMID:20037814 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
affects expression |
ISO |
Daunorubicin affects the expression of CDKN2A mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
increases expression |
ISO |
Daunorubicin results in increased expression of CDKN2B mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
increases expression |
ISO |
Daunorubicin results in increased expression of CEACAM1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Cebpz |
CCAAT/enhancer binding protein zeta |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CEBPZ mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:16,119,871...16,137,600
Ensembl chr 6:16,119,872...16,137,600
|
|
G |
Ckm |
creatine kinase, M-type |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CKM mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Clybl |
citramalyl-CoA lyase |
affects response to substance |
ISO |
CLYBL affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr15:99,283,644...99,505,697
Ensembl chr15:99,283,650...99,505,695
|
|
G |
Cmc2 |
C-x(9)-C motif containing 2 |
affects response to substance |
ISO |
CMC2 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr19:44,943,283...44,997,408
Ensembl chr19:44,943,285...44,971,983
|
|
G |
Cmip |
c-Maf-inducing protein |
affects response to substance |
ISO |
CMIP affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr19:45,304,597...45,510,653
Ensembl chr19:45,304,031...45,508,709
|
|
G |
Corin |
corin, serine peptidase |
decreases expression |
ISO |
Daunorubicin results in decreased expression of CORIN mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr14:35,680,601...35,910,703
Ensembl chr14:35,681,304...35,909,503
|
|
G |
Cwc27 |
CWC27 spliceosome associated cyclophilin |
affects response to substance |
ISO |
CWC27 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 2:35,764,674...35,975,908
Ensembl chr 2:35,764,686...35,975,872
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression |
EXP |
Daunorubicin results in decreased expression of CXCR4 mRNA |
CTD |
PMID:27090888 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions increases expression |
EXP |
telmisartan inhibits the reaction [Daunorubicin results in increased expression of CYBA protein] |
CTD |
PMID:21054405 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
increases expression |
EXP |
Daunorubicin results in increased expression of CYBB mRNA |
CTD |
PMID:27090888 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cycs |
cytochrome c, somatic |
affects expression |
ISO |
Daunorubicin affects the expression of CYCS mRNA |
CTD |
PMID:27780733 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
affects response to substance |
ISO |
CYP1B1 affects the susceptibility to Daunorubicin |
CTD |
PMID:18451141 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Dffa |
DNA fragmentation factor subunit alpha |
increases degradation |
ISO |
Daunorubicin results in increased degradation of DFFA protein |
CTD |
PMID:12370496 |
|
NCBI chr 5:159,540,718...159,553,639
Ensembl chr 5:159,540,715...159,553,633
|
|
G |
Dmd |
dystrophin |
decreases expression |
ISO |
Daunorubicin results in decreased expression of DMD mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
increases expression |
ISO |
Daunorubicin results in increased expression of DUSP4 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
|
|
G |
E2f5 |
E2F transcription factor 5 |
increases expression |
ISO |
Daunorubicin results in increased expression of E2F5 mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 2:86,997,331...87,012,901
Ensembl chr 2:86,997,332...87,012,990
|
|
G |
Edn1 |
endothelin 1 |
increases expression multiple interactions |
EXP |
Daunorubicin results in increased expression of EDN1 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of EDN1 protein] |
CTD |
PMID:20888384 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednra |
endothelin receptor type A |
increases expression multiple interactions |
EXP |
Daunorubicin results in increased expression of EDNRA protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of EDNRA protein] |
CTD |
PMID:20888384 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Ednrb |
endothelin receptor type B |
increases expression multiple interactions |
EXP |
Daunorubicin results in increased expression of EDNRB protein telmisartan promotes the reaction [Daunorubicin results in increased expression of EDNRB protein] |
CTD |
PMID:20888384 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
Daunorubicin inhibits the reaction [EGF protein results in increased abundance of Diglycerides] |
CTD |
PMID:11082532 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Ei24 |
EI24, autophagy associated transmembrane protein |
increases expression |
ISO |
Daunorubicin results in increased expression of EI24 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 8:36,494,289...36,510,653
Ensembl chr 8:36,494,289...36,510,571
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
increases phosphorylation multiple interactions |
ISO |
Daunorubicin results in increased phosphorylation of EIF4EBP1 protein Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:21898527 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eng |
endoglin |
decreases expression |
EXP |
Daunorubicin results in decreased expression of ENG mRNA |
CTD |
PMID:27090888 |
|
NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230
|
|
G |
Epm2aip1 |
EPM2A interacting protein 1 |
increases expression |
ISO |
Daunorubicin results in increased expression of EPM2AIP1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 8:111,233,871...111,241,219
Ensembl chr 8:111,233,826...111,241,871
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of ERBB3 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases activity increases activity |
ISO |
Daunorubicin results in decreased activity of ESR1 protein Daunorubicin results in increased activity of ESR1 protein |
CTD |
PMID:25257666 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
Daunorubicin results in increased expression of F3 mRNA; Daunorubicin results in increased expression of F3 protein |
CTD |
PMID:11721405 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
Daunorubicin results in increased expression of FAS mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression |
EXP |
candesartan inhibits the reaction [Daunorubicin results in increased expression of FASLG protein] |
CTD |
PMID:16324756 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fdxr |
ferredoxin reductase |
increases expression |
ISO |
Daunorubicin results in increased expression of FDXR mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658
|
|
G |
Gapt |
Grb2-binding adaptor protein, transmembrane |
affects response to substance |
ISO |
GAPT affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 2:41,927,533...41,932,120
Ensembl chr 2:41,927,532...41,932,093
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
Daunorubicin results in increased expression of GDF15 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr16:18,805,312...18,807,893
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gpc5 |
glypican 5 |
affects response to substance |
ISO |
GPC5 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr15:92,207,275...93,644,054
Ensembl chr15:92,239,176...93,643,282
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
Daunorubicin results in increased expression of GPX1 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
affects response to substance |
ISO |
GSTM1 gene polymorphism affects the susceptibility to Daunorubicin |
CTD |
PMID:15713801 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
H2ax |
H2A.X variant histone |
affects expression |
ISO |
Daunorubicin affects the expression of H2AX mRNA |
CTD |
PMID:27780733 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hnrnpd |
heterogeneous nuclear ribonucleoprotein D |
affects response to substance |
ISO |
HNRNPD affects the susceptibility to Daunorubicin |
CTD |
PMID:18451141 |
|
NCBI chr14:9,615,375...9,638,975
Ensembl chr14:9,615,479...9,633,786
|
|
G |
Hrc |
histidine rich calcium binding protein |
decreases expression |
ISO |
Daunorubicin results in decreased expression of HRC mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:95,813,262...95,816,987
Ensembl chr 1:95,813,253...95,816,984
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression multiple interactions |
EXP |
Daunorubicin results in increased expression of ICAM1 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of ICAM1 protein] |
CTD |
PMID:20888384 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ikbke |
inhibitor of nuclear factor kappa B kinase subunit epsilon |
affects response to substance |
ISO |
IKBKE affects the susceptibility to Daunorubicin |
CTD |
PMID:18451141 |
|
NCBI chr13:42,712,154...42,738,470
Ensembl chr13:42,712,159...42,737,143
|
|
G |
Il6r |
interleukin 6 receptor |
decreases expression |
ISO |
Daunorubicin results in decreased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Ilkap |
ILK associated serine/threonine phosphatase |
affects response to substance |
ISO |
ILKAP affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 9:91,966,440...91,988,791
Ensembl chr 9:91,966,441...91,988,892
|
|
G |
Inpp4b |
inositol polyphosphate-4-phosphatase type II B |
affects response to substance |
ISO |
INPP4B affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr19:25,920,189...26,670,085
Ensembl chr19:25,925,358...26,280,634
|
|
G |
Irx4 |
iroquois homeobox 4 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of IRX4 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:30,030,561...30,039,549
Ensembl chr 1:30,030,561...30,039,549
|
|
G |
Jak2 |
Janus kinase 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of JAK2 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of KCNH2 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj2 |
potassium inwardly-rectifying channel, subfamily J, member 2 |
increases expression |
ISO |
Daunorubicin results in increased expression of KCNJ2 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr10:96,060,849...96,071,401
Ensembl chr10:96,060,821...96,071,445
|
|
G |
Kcnq1 |
potassium voltage-gated channel subfamily Q member 1 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of KCNQ1 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669
|
|
G |
Kif1a |
kinesin family member 1A |
affects response to substance |
ISO |
KIF1A affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 9:93,563,033...93,647,412
Ensembl chr 9:93,563,045...93,647,480
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression |
EXP |
Daunorubicin results in decreased expression of KIT mRNA |
CTD |
PMID:27090888 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Kitlg |
KIT ligand |
decreases expression |
EXP |
Daunorubicin results in decreased expression of KITLG mRNA |
CTD |
PMID:27090888 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Krt19 |
keratin 19 |
increases expression |
EXP |
Daunorubicin results in increased expression of KRT19 protein |
CTD |
PMID:2444108 |
|
NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt8 |
keratin 8 |
increases expression |
EXP |
Daunorubicin results in increased expression of KRT8 protein |
CTD |
PMID:2444108 |
|
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
|
|
G |
Ldb3 |
LIM domain binding 3 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of LDB3 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr16:9,855,768...9,920,108
Ensembl chr16:9,855,927...9,918,532
|
|
G |
LOC102556347 |
carbonyl reductase [NADPH] 1-like |
increases reduction increases metabolic processing multiple interactions decreases metabolic processing |
ISO |
CBR1 protein results in increased reduction of Daunorubicin CBR1 protein results in increased metabolism of Daunorubicin; CBR1 results in increased metabolism of Daunorubicin 8-prenylnaringenin inhibits the reaction [CBR1 protein results in increased metabolism of Daunorubicin]; [[Curcumin binds to and results in decreased activity of CBR1 protein] which results in decreased reduction of Daunorubicin] which results in decreased chemical synthesis of daunorubicinol; [CBR1 protein results in increased reduction of Daunorubicin] which results in increased chemical synthesis of daunorubicinol; [CBR1 results in increased metabolism of Daunorubicin] which results in increased chemical synthesis of daunorubicinol; [Curcumin binds to and results in decreased activity of CBR1 protein] which results in decreased reduction of Daunorubicin; [S-Nitrosoglutathione binds to CBR1 protein] inhibits the reaction [CBR1 protein results in increased metabolism of Daunorubicin]; isoxanthohumol inhibits the reaction [CBR1 protein results in increased metabolism of Daunorubicin]; xanthohumol inhibits the reaction [CBR1 protein results in increased metabolism of Daunorubicin] CBR1 gene SNP results in decreased metabolism of Daunorubicin |
CTD |
PMID:18579125 PMID:19204081 PMID:20670211 PMID:23295225 PMID:25541467 PMID:30849340 More...
|
|
NCBI chr11:32,892,640...32,895,277
Ensembl chr11:32,857,991...32,895,275
|
|
G |
LOC499643 |
similar to hypothetical protein FLJ25371 |
affects response to substance |
ISO |
C4ORF45 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 2:164,490,211...164,604,379
Ensembl chr 2:164,490,252...164,604,379
|
|
G |
Lsamp |
limbic system-associated membrane protein |
affects response to substance |
ISO |
LSAMP affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr11:58,547,533...60,717,329
Ensembl chr11:58,554,805...60,717,029
|
|
G |
Luzp2 |
leucine zipper protein 2 |
affects response to substance |
ISO |
LUZP2 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 1:105,597,291...105,983,605
Ensembl chr 1:105,597,307...105,981,183
|
|
G |
Map1b |
microtubule-associated protein 1B |
affects response to substance |
ISO |
MAP1B affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 2:30,817,261...30,910,458
Ensembl chr 2:30,817,261...30,910,317
|
|
G |
Map2k3 |
mitogen activated protein kinase kinase 3 |
increases expression |
ISO |
Daunorubicin results in increased expression of MAP2K3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of MAP3K5 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression |
ISO |
Daunorubicin results in decreased expression of MAPT mRNA; Daunorubicin results in decreased expression of MAPT protein |
CTD |
PMID:16930453 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mdm4 |
MDM4 regulator of p53 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of MDM4 mRNA |
CTD |
PMID:12656675 |
|
NCBI chr13:44,432,596...44,516,165
Ensembl chr13:44,406,213...44,474,226
|
|
G |
Mir21 |
microRNA 21 |
decreases response to substance |
ISO |
MIR21 results in decreased susceptibility to Daunorubicin |
CTD |
PMID:21187093 |
|
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
|
|
G |
Mt1 |
metallothionein 1 |
increases expression multiple interactions |
EXP |
Daunorubicin results in increased expression of MT1A mRNA; Daunorubicin results in increased expression of MT1A protein Zinc promotes the reaction [Daunorubicin results in increased expression of MT1A mRNA]; Zinc promotes the reaction [Daunorubicin results in increased expression of MT1A protein] |
CTD |
PMID:12204545 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation multiple interactions |
ISO |
Daunorubicin results in increased phosphorylation of MTOR protein Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of MTOR protein] |
CTD |
PMID:21898527 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myh6 |
myosin heavy chain 6 |
decreases expression |
ISO EXP |
Daunorubicin results in decreased expression of MYH6 mRNA |
CTD |
PMID:26537877 PMID:27090888 PMID:28940058 |
|
NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Myh7 |
myosin heavy chain 7 |
increases expression decreases expression |
EXP ISO |
Daunorubicin results in increased expression of MYH7 mRNA Daunorubicin results in decreased expression of MYH7 mRNA |
CTD |
PMID:26328012 PMID:26537877 PMID:27090888 PMID:28940058 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Myom2 |
myomesin 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of MYOM2 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr16:74,520,148...74,592,658
Ensembl chr16:74,520,157...74,592,772
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions increases expression |
EXP |
telmisartan inhibits the reaction [Daunorubicin results in increased expression of NCF1 protein] |
CTD |
PMID:21054405 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
increases expression multiple interactions |
EXP |
Daunorubicin results in increased expression of NCF2 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of NCF2 protein] |
CTD |
PMID:21054405 |
|
NCBI chr13:64,955,502...64,986,289
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Nck2 |
NCK adaptor protein 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of NCK2 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:45,713,979...45,840,330
Ensembl chr 9:45,714,883...45,840,307
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
Daunorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]] |
CTD |
PMID:25257666 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Ngef |
neuronal guanine nucleotide exchange factor |
affects response to substance |
ISO |
NGEF affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 9:88,146,956...88,244,454
Ensembl chr 9:88,146,956...88,244,914
|
|
G |
Nox4 |
NADPH oxidase 4 |
increases expression multiple interactions |
EXP |
Daunorubicin results in increased expression of NOX4 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of NOX4 protein] |
CTD |
PMID:21054405 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Npc1 |
NPC intracellular cholesterol transporter 1 |
multiple interactions increases secretion affects response to substance |
ISO |
Nocodazole inhibits the reaction [NPC1 protein results in increased secretion of Daunorubicin]; Progesterone inhibits the reaction [NPC1 protein results in increased secretion of Daunorubicin] NPC1 affects the susceptibility to Daunorubicin |
CTD |
PMID:16174794 |
|
NCBI chr18:3,379,482...3,425,100
Ensembl chr18:3,379,482...3,425,049
|
|
G |
Nppa |
natriuretic peptide A |
increases expression |
EXP |
Daunorubicin results in increased expression of NPPA mRNA |
CTD |
PMID:26328012 PMID:27090888 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
decreases expression increases expression |
EXP ISO |
Daunorubicin results in decreased expression of NPPB mRNA; Daunorubicin results in decreased expression of NPPB protein Daunorubicin results in increased expression of NPPB mRNA Daunorubicin results in increased expression of NPPB protein |
CTD |
PMID:11279304 PMID:17673002 PMID:26328012 PMID:27090888 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases activity decreases expression |
EXP ISO |
Daunorubicin results in increased activity of NQO1 protein Daunorubicin results in decreased expression of NQO1 mRNA; Daunorubicin results in decreased expression of NQO1 protein |
CTD |
PMID:3986001 PMID:8875677 PMID:9620540 PMID:22021338 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions decreases activity increases activity |
ISO |
Daunorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Daunorubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Daunorubicin inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] Daunorubicin results in decreased activity of NR1H4 protein Daunorubicin results in increased activity of NR1H4 protein |
CTD |
PMID:25257666 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
decreases activity |
ISO |
Daunorubicin results in decreased activity of NR3C1 protein |
CTD |
PMID:19255438 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nrap |
nebulin-related anchoring protein |
decreases expression |
ISO |
Daunorubicin results in decreased expression of NRAP mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:255,350,113...255,427,704
Ensembl chr 1:255,350,113...255,427,693
|
|
G |
Nras |
NRAS proto-oncogene, GTPase |
increases expression |
ISO |
Daunorubicin results in increased expression of NRAS mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions affects expression increases cleavage |
ISO |
[Daunorubicin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein Daunorubicin affects the expression of PARP1 mRNA Daunorubicin results in increased cleavage of PARP1 protein |
CTD |
PMID:10766178 PMID:11082532 PMID:12780785 PMID:27780733 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pfkm |
phosphofructokinase, muscle |
decreases expression |
EXP |
Daunorubicin results in decreased expression of PFKM mRNA |
CTD |
PMID:9038198 |
|
NCBI chr 7:129,221,679...129,259,192
Ensembl chr 7:129,221,653...129,259,192
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
affects response to substance |
ISO |
PIK3R1 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 2:32,878,942...32,963,611
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions |
ISO |
[Daunorubicin results in increased abundance of Ceramides] which results in increased secretion of PLAT protein |
CTD |
PMID:11107162 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plk3 |
polo-like kinase 3 |
increases expression |
ISO |
Daunorubicin results in increased expression of PLK3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 5:130,607,142...130,612,317
Ensembl chr 5:130,607,142...130,612,317
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression |
EXP |
Daunorubicin results in increased expression of PPARA mRNA |
CTD |
PMID:23834779 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions decreases activity |
EXP ISO |
[Enalaprilat co-treated with Daunorubicin] results in increased expression of PPARD mRNA Daunorubicin results in decreased activity of PPARD protein |
CTD |
PMID:23834779 PMID:25257666 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions decreases activity increases expression |
EXP ISO |
telmisartan promotes the reaction [Daunorubicin results in increased expression of PPARG protein] Daunorubicin results in decreased activity of PPARG protein |
CTD |
PMID:20888384 PMID:25257666 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp1r13l |
protein phosphatase 1, regulatory subunit 13 like |
decreases response to substance |
ISO |
PPP1R13L results in decreased susceptibility to Daunorubicin |
CTD |
PMID:19299014 |
|
NCBI chr 1:79,010,997...79,030,714
Ensembl chr 1:79,011,745...79,030,712
|
|
G |
Ppp1r3a |
protein phosphatase 1, regulatory subunit 3A |
decreases expression |
ISO |
Daunorubicin results in decreased expression of PPP1R3A mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 4:42,937,353...42,980,195
Ensembl chr 4:42,939,599...42,980,638
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of PRC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
|
|
G |
Prdm16 |
PR/SET domain 16 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of PRDM16 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 5:164,879,864...165,203,986
Ensembl chr 5:164,880,587...165,203,601
|
|
G |
Prkcd |
protein kinase C, delta |
increases cleavage |
ISO |
Daunorubicin results in increased cleavage of PRKCD protein |
CTD |
PMID:11082532 |
|
NCBI chr16:5,769,226...5,807,214
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prkcz |
protein kinase C, zeta |
decreases response to substance |
ISO |
PRKCZ protein results in decreased susceptibility to Daunorubicin |
CTD |
PMID:21863889 |
|
NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367
|
|
G |
Prkx |
protein kinase, X-linked |
increases expression |
ISO |
Daunorubicin results in increased expression of PRKX mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr X:41,823,349...41,866,844
Ensembl chr X:41,823,355...41,866,669
|
|
G |
Prom1 |
prominin 1 |
decreases expression |
EXP |
Daunorubicin results in decreased expression of PROM1 mRNA |
CTD |
PMID:27090888 |
|
NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527
|
|
G |
Pten |
phosphatase and tensin homolog |
increases response to substance |
ISO |
PTEN results in increased susceptibility to Daunorubicin |
CTD |
PMID:21187093 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
EXP |
Daunorubicin results in increased expression of PTGS2 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of PTGS2 protein] |
CTD |
PMID:20888384 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pygm |
glycogen phosphorylase, muscle associated |
decreases expression |
ISO |
Daunorubicin results in decreased expression of PYGM mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:203,690,550...203,705,369
Ensembl chr 1:203,690,533...203,705,368
|
|
G |
Ranbp17 |
RAN binding protein 17 |
affects response to substance |
ISO |
RANBP17 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr10:17,800,406...18,102,947
Ensembl chr10:17,800,999...18,102,831
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
increases expression |
ISO |
Daunorubicin results in increased expression of RB1 mRNA |
CTD |
PMID:12656675 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rbbp5 |
RB binding protein 5, histone lysine methyltransferase complex subunit |
affects expression |
ISO |
Daunorubicin affects the expression of RBBP5 mRNA |
CTD |
PMID:12656675 |
|
NCBI chr13:43,912,254...43,939,107
Ensembl chr13:43,912,254...43,939,107
|
|
G |
Rbbp6 |
RB binding protein 6, ubiquitin ligase |
increases expression |
ISO |
Daunorubicin results in increased expression of RBBP6 mRNA |
CTD |
PMID:12656675 |
|
NCBI chr 1:177,503,988...177,537,397
Ensembl chr 1:177,503,313...177,535,678
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[Daunorubicin co-treated with Magnetite Nanoparticles] results in decreased expression of RELA protein |
CTD |
PMID:21518493 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
affects expression multiple interactions |
EXP |
Daunorubicin affects the expression of ROCK1 mRNA fasudil affects the reaction [Daunorubicin affects the expression of ROCK1 mRNA] |
CTD |
PMID:20037814 |
|
NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases phosphorylation decreases expression multiple interactions |
ISO EXP |
Daunorubicin results in increased phosphorylation of RPS6KB1 protein Daunorubicin results in decreased expression of RPS6KB1 mRNA Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:21898527 PMID:28099878 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Ryr2 |
ryanodine receptor 2 |
multiple interactions decreases expression increases expression |
EXP ISO |
Razoxane inhibits the reaction [Daunorubicin results in decreased expression of RYR2 mRNA] Daunorubicin results in increased expression of RYR2 protein |
CTD |
PMID:10960060 PMID:26328012 PMID:26537877 PMID:28940058 |
|
NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142
|
|
G |
Scn2b |
sodium voltage-gated channel beta subunit 2 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of SCN2B mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 8:45,425,629...45,437,765
Ensembl chr 8:45,425,629...45,437,765
|
|
G |
Scn5a |
sodium voltage-gated channel alpha subunit 5 |
decreases expression |
ISO |
Daunorubicin results in decreased expression of SCN5A mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 8:119,220,905...119,318,816
Ensembl chr 8:119,220,905...119,318,769
|
|
G |
Sdc1 |
syndecan 1 |
increases expression |
ISO |
Daunorubicin results in increased expression of SDC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:31,562,799...31,585,267
Ensembl chr 6:31,562,739...31,585,264
|
|
G |
Serpine1 |
serpin family E member 1 |
decreases expression decreases secretion multiple interactions |
ISO EXP |
Daunorubicin results in decreased expression of SERPINE1 mRNA; Daunorubicin results in decreased expression of SERPINE1 protein Daunorubicin results in decreased secretion of SERPINE1 protein [Daunorubicin results in increased abundance of Ceramides] which results in decreased secretion of SERPINE1 protein; fumonisin B1 inhibits the reaction [Daunorubicin results in decreased expression of SERPINE1 protein] |
CTD |
PMID:11107162 PMID:11336794 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc22a16 |
solute carrier family 22 member 16 |
multiple interactions |
ISO |
Daunorubicin inhibits the reaction [SLC22A16 protein results in increased uptake of Doxorubicin] |
CTD |
PMID:15963465 |
|
NCBI chr20:43,972,808...44,068,447
Ensembl chr20:43,972,836...44,065,019
|
|
G |
Slc25a4 |
solute carrier family 25 member 4 |
decreases expression |
EXP |
Daunorubicin results in decreased expression of SLC25A4 mRNA |
CTD |
PMID:9038198 |
|
NCBI chr16:46,072,935...46,076,730
Ensembl chr16:46,072,939...46,076,733
|
|
G |
Slit3 |
slit guidance ligand 3 |
affects response to substance |
ISO |
SLIT3 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr10:19,571,798...20,156,634
Ensembl chr10:19,571,684...20,156,634
|
|
G |
Smpd1 |
sphingomyelin phosphodiesterase 1 |
increases expression increases activity |
ISO |
Daunorubicin results in increased expression of SMPD1 mRNA Daunorubicin results in increased activity of SMPD1 protein |
CTD |
PMID:19698806 |
|
NCBI chr 1:159,892,946...159,896,789
Ensembl chr 1:159,892,859...159,896,794
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3 |
increases expression increases response to substance |
ISO |
Daunorubicin results in increased expression of SMPD3 mRNA; Daunorubicin results in increased expression of SMPD3 protein SMPD3 results in increased susceptibility to Daunorubicin |
CTD |
PMID:19698806 |
|
NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases secretion multiple interactions |
EXP |
Daunorubicin results in decreased secretion of SOD2 protein nebivolol inhibits the reaction [Daunorubicin results in decreased secretion of SOD2 protein] |
CTD |
PMID:18194856 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sp110 |
SP110 nuclear body protein |
affects response to substance |
ISO |
SP110 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 9:86,200,503...86,225,355
Ensembl chr 9:86,200,503...86,222,670
|
|
G |
Sp3 |
Sp3 transcription factor |
increases expression |
ISO |
Daunorubicin results in increased expression of SP3 protein |
CTD |
PMID:19698806 |
|
NCBI chr 3:57,811,855...57,857,150
Ensembl chr 3:57,812,075...57,860,342
|
|
G |
Tagln3 |
transgelin 3 |
affects response to substance |
ISO |
TAGLN3 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr11:55,099,887...55,113,457
Ensembl chr11:55,099,743...55,113,485
|
|
G |
Tap1 |
transporter 1, ATP binding cassette subfamily B member |
increases expression |
ISO |
Daunorubicin results in increased expression of TAP1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901
|
|
G |
Tap2 |
transporter 2, ATP binding cassette subfamily B member |
affects response to substance |
ISO |
TAP2 affects the susceptibility to Daunorubicin |
CTD |
PMID:18451141 |
|
NCBI chr20:4,636,347...4,650,387
Ensembl chr20:4,636,357...4,650,407
|
|
G |
Tax1bp3 |
Tax1 binding protein 3 |
increases expression |
ISO |
Daunorubicin results in increased expression of TAX1BP3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:57,795,785...57,800,363
Ensembl chr10:57,795,382...57,800,363
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression |
EXP |
telmisartan inhibits the reaction [Daunorubicin results in increased expression of TGFB1 protein] |
CTD |
PMID:20888384 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr4 |
toll-like receptor 4 |
decreases response to substance |
ISO |
TLR4 protein results in decreased susceptibility to Daunorubicin |
CTD |
PMID:18789402 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tm4sf20 |
transmembrane 4 L six family member 20 |
affects response to substance |
ISO |
TM4SF20 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr 9:84,038,715...84,052,615
Ensembl chr 9:84,038,715...84,052,615
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
Daunorubicin results in increased expression of TNF protein |
CTD |
PMID:16626513 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
multiple interactions |
ISO |
Daunorubicin promotes the reaction [TNFSF10 results in increased expression of TNFRSF10A mRNA] |
CTD |
PMID:17204177 |
|
NCBI chr15:44,839,818...44,867,582
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
[Daunorubicin co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; [Daunorubicin co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Daunorubicin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [Daunorubicin co-treated with TNFSF10 protein] results in increased expression of BID protein; Daunorubicin promotes the reaction [TNFSF10 results in increased expression of TNFRSF10A mRNA]; Daunorubicin promotes the reaction [TNFSF10 results in increased expression of TNFRSF10B mRNA] |
CTD |
PMID:12780785 PMID:17204177 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnfsf9 |
TNF superfamily member 9 |
increases expression |
ISO |
Daunorubicin results in increased expression of TNFSF9 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:1,944,017...1,946,351
Ensembl chr 9:1,944,017...1,946,345
|
|
G |
Tnnt1 |
troponin T1, slow skeletal type |
decreases expression |
ISO |
Daunorubicin results in decreased expression of TNNT1 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 1:69,306,362...69,316,721
Ensembl chr 1:69,306,362...69,316,721
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
multiple interactions increases secretion |
EXP |
nebivolol inhibits the reaction [Daunorubicin results in increased expression of TNNT2 protein] Daunorubicin results in increased secretion of TNNT2 protein |
CTD |
PMID:18194856 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases activity increases expression |
ISO |
[Daunorubicin co-treated with Magnetite Nanoparticles] results in increased activity of TP53 protein; Daunorubicin results in increased phosphorylation of and results in increased expression of TP53 protein Daunorubicin results in increased activity of TP53 protein Daunorubicin results in increased expression of TP53 mRNA |
CTD |
PMID:12112851 PMID:12656675 PMID:21518493 PMID:23872705 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53i3 |
tumor protein p53 inducible protein 3 |
increases expression |
ISO |
Daunorubicin results in increased expression of TP53I3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:27,818,327...27,827,030
|
|
G |
Tyms |
thymidylate synthetase |
affects response to substance |
ISO |
TYMS gene polymorphism affects the susceptibility to Daunorubicin |
CTD |
PMID:15713801 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Uqcrfs1 |
ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 |
decreases expression |
EXP |
Daunorubicin results in decreased expression of UQCRFS1 mRNA |
CTD |
PMID:9038198 |
|
NCBI chr17:33,977,908...33,982,478
Ensembl chr17:33,977,921...33,982,479
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression multiple interactions |
EXP |
Daunorubicin results in increased expression of VCAM1 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of VCAM1 protein] |
CTD |
PMID:20888384 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vdr |
vitamin D receptor |
affects response to substance decreases activity |
ISO |
VDR gene polymorphism affects the susceptibility to Daunorubicin Daunorubicin results in decreased activity of VDR protein |
CTD |
PMID:15713801 PMID:25257666 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO EXP |
Daunorubicin results in decreased expression of VEGFA protein Daunorubicin results in decreased expression of VEGFA mRNA |
CTD |
PMID:20116850 PMID:27090888 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
increases expression |
EXP |
Daunorubicin results in increased expression of VIM protein |
CTD |
PMID:2444108 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Zbtb20 |
zinc finger and BTB domain containing 20 |
affects response to substance |
ISO |
ZBTB20 affects the susceptibility to Daunorubicin |
CTD |
PMID:17545624 |
|
NCBI chr11:57,052,129...57,823,679
Ensembl chr11:57,072,880...57,510,210
|
|
G |
Zmat3 |
zinc finger, matrin type 3 |
increases expression |
ISO |
Daunorubicin results in increased expression of ZMAT3 mRNA |
CTD |
PMID:26537877 PMID:28940058 |
|
NCBI chr 2:115,106,050...115,136,863
Ensembl chr 2:115,106,966...115,136,863
|
|